NASDAQ:CHFS - Nuwellis Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.00
  • Forecasted Upside: 379.62 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.17
▼ -0.24 (-5.44%)
Get New Nuwellis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CHFS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CHFS

Analyst Price Target is $20.00
▲ +379.62% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Nuwellis in the last 3 months. The average price target is $20.00, with a high forecast of $20.00 and a low forecast of $20.00. The average price target represents a 379.62% upside from the last price of $4.17.

This chart shows the closing price for CHFS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Nuwellis.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/28/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/12/2020Maxim GroupReiterated RatingBuyLow
10/21/2020Maxim GroupLower Price Target$45.00 ➝ $20.00Low
6/5/2020Maxim GroupInitiated CoverageBuy$1.50High
8/28/2018Dawson JamesInitiated CoverageBuy$3.30High
6/29/2017LADENBURG THALM/SH SHInitiated CoverageBuy$65.00High
11/29/2016S&P Equity ResearchBoost Price Target$0.18 ➝ $0.23N/A
(Data available from 6/21/2016 forward)
Nuwellis logo
Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
Read More

Today's Range

Now: $4.17
Low: $4.17
High: $4.49

50 Day Range

MA: $4.79
Low: $3.53
High: $6.02

52 Week Range

Now: $4.17
Low: $4.86
High: $37.50

Volume

139,017 shs

Average Volume

467,323 shs

Market Capitalization

$25.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Nuwellis?

The following Wall Street sell-side analysts have issued reports on Nuwellis in the last year: Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for CHFS.

What is the current price target for Nuwellis?

1 Wall Street analysts have set twelve-month price targets for Nuwellis in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 379.6%. Maxim Group has the highest price target set, predicting CHFS will reach $20.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $20.00 for Nuwellis in the next year.
View the latest price targets for CHFS.

What is the current consensus analyst rating for Nuwellis?

Nuwellis currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CHFS will outperform the market and that investors should add to their positions of Nuwellis.
View the latest ratings for CHFS.

What other companies compete with Nuwellis?

How do I contact Nuwellis' investor relations team?

Nuwellis' physical mailing address is 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN, 55344. The company's listed phone number is (952) 345-4200 and its investor relations email address is [email protected] The official website for Nuwellis is www.chf-solutions.com.